Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.
Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.
Omer Hassan Jamy, MD, highlights...